Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case series is unique in its focus on the intracran...

Повний опис

Бібліографічні деталі

Автори:	Illaa Smesseim, MD, Tijmen van der Wel, MD, Sushil K. Badrising, MD, PhD
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2024-12-01
Серія:	JTO Clinical and Research Reports
Предмети:	RET Selpercatinib Non–small-cell lung carcinoma RET fusion NSCLC Case Report
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2666364324001000
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!